Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Article excerpt
Highlighted: the sentence this signal was extracted from
GLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a transformation for some long-standing firms in the space. Bristol-Myers Squibb BMY recently announced that its investigational drug candidate iza-brentuximab (Iza-bren) demonstrated a reduction in the risk of progression or death in a breast cancer trial. The Phase 3 trial data comes at a crucial time for the firm as it faces the ongoing threats of a major patent cliff for its popular blood cancer drug Revlimid. At its peak, this drug commanded annual sales of nearly $13 billion, but that was in 2021, and generic competition has eroded those sales in the years since. Given that breast cancer is the largest oncology indication across the country, any drug that can meaningfully boost progression-free survival has the potential to become another multi-billion-dollar venture. The Potential Implications of the Iza-bren Trial Data The Iza-bren trial in question focused on patients with HER2-low and HER2-ultra low metastatic cancers, common types of breast cancers that represent up to about two-thirds of all metastatic breast cancer cases. Despite the prevalence of these cancers, they are currently underserved by existing therapies. The Phase 3 trial data showed a 59% reduction in the risk...
Keep reading with a free account
The rest of this article, and every signal for Bristol Myers Squibb, is in your free account.
